Novel pharmacological agents in clinical development for solid tumours
- 1 December 2001
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 10 (12) , 2059-2088
- https://doi.org/10.1517/13543784.10.12.2059
Abstract
For decades, cancer therapy has focused on DNA-directed mechanisms of cytotoxicity, utilising agents with limited efficacy and significant toxicity. Recent advances in tumour biology have elucidated the molecular pathways implicated in the pathogenesis and progression of cancers and have resulted in the discovery of a variety of novel molecular targets for therapeutic intervention. Promising novel agents targeting signal transduction pathways, cell cycle regulation, angiogenesis and apoptosis are in clinical testing and are discussed in this review.Keywords
This publication has 39 references indexed in Scilit:
- Blocking Oncogenic Ras Signaling for Cancer TherapyJNCI Journal of the National Cancer Institute, 2001
- Signal Transduction Pathway Targets for Anticancer Drug DiscoveryCurrent Pharmaceutical Design, 2000
- Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced CancerJournal of Clinical Oncology, 2000
- Epidermal growth factor-related peptides and their receptors in human malignanciesPublished by Elsevier ,2000
- Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and RadiationCancer Biotherapy & Radiopharmaceuticals, 1999
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin.Gastroenterology, 1997
- Antitumor Activity of a Monoclonal Antibody Directed Against Gastrin-Releasing Peptide in Patients With Small Cell Lung CancerChest, 1997
- Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancerNature, 1985
- Autocrine growth factors and cancerNature, 1985